In 2026, environmental control measures in the pharmaceutical industry will continue to become stricter, and many pharmaceutical factories will face technological upgrades. Raw materials CDMO、 Most pharmaceutical intermediate factories produce in batches intermittently. The release of pressure from reaction vessels, vacuum drying, and vacuum pump exhaust will intermittently produce a large amount of VOCs organic exhaust gas. The exhaust gas contains high-value solvents such as dichloromethane, acetone, and ethyl acetate, and the concentration of the exhaust gas fluctuates greatly. Some media hydrolyze to produce chloride ions, which poses a corrosion risk. The production area belongs to Class A explosion-proof environment. When choosing a solvent liquefaction recovery device, enterprises should not only consider the equipment quotation, but also take into account the recovery efficiency, explosion-proof safety, and corrosion resistance. At the same time, they should not interfere with the negative pressure production of the reaction kettle and vacuum pump. Choosing the right source manufacturer can greatly reduce the risk of later operation and maintenance failures.
Many pharmaceutical factories use traditional processing techniques in the early stages, but their actual operation exposes many shortcomings.RTOThe incineration process directly destroys organic solvents at high temperatures, losing the value of solvent recovery. The treatment of halogenated hydrocarbon waste gas containing dichloromethane also easily generates corrosive by-products, resulting in high equipment investment and fuel consumption costs.activated charcoalAdsorption of pharmaceutical waste gas with intermittent fluctuations is prone to rapid saturation, requiring frequent replacement of activated carbon and generating a large amount of hazardous waste. The cost of hazardous waste disposal has been increasing year by year, and can only achieve waste gas purification, but cannot achieve solvent liquefaction recovery and reuse. Simple single-stage condensing equipment requires deep refrigeration to improve recovery rate, resulting in high overall energy consumption and easily exceeding exhaust emissions when encountering concentration shocks. A single membrane device can only perform gas enrichment and cannot directly produce liquid solvents. Under high load conditions, membrane components lose quickly.
The compression condensation membrane coupled solvent liquefaction recovery device is the mainstream technology route for resource recovery in pharmaceutical factories in 2026. The entire set is a physical recovery process without open flames. Intermittent exhaust gas first enters the buffering and stabilizing unit to stabilize concentration shock, and then undergoes foam removal filtration, pre cooling and dehydration pretreatment to filter out drug mist, impurities, and water vapor, protecting the condenser and membrane components. The exhaust gas is compressed and pressurized to increase the partial pressure of solvent vapor, and most of the organic solvents are directly liquefied and recovered in the multi-stage gradient condensation unit; The residual exhaust gas that has not been completely condensed is sent to the halogenated hydrocarbon resistant membrane module for enrichment and separation. The concentrated high concentration organic gas is circulated in the front-end of the reflux equipment for treatment. The treated exhaust gas meets the emission standards. The collected liquid solvent is sent back to the production workshop for reuse after phase separation treatment.
In the selection of VOCs solvent liquefaction recovery equipment for pharmaceutical factories in 2026, several core points should be grasped. The first refusal is to directly apply standard models, as there are significant differences in pharmaceutical operating conditions. Manufacturers need to combine actual air volume, solvent composition, water content, and intermittent production cycles to complete material balance calculations, calculate solvent recovery, overall energy consumption, and investment return period. The second treatment of halogenated hydrocarbon waste gas containing dichloromethane requires the use of a specialized halogenated hydrocarbon resistant membrane. Ordinary organic membranes that come into contact with halogenated hydrocarbons will quickly swell and fail. The third preprocessing system cannot be deleted. Buffer, foam removal, filtration, and pre cooling dehydration are the key to extending the service life of the entire equipment. The fourth focus is on back pressure control. Improper design of equipment flow channels can increase front-end pressure and damage the negative pressure environment of reaction vessels and vacuum pumps. The explosion-proof level of the fifth equipment must match the Class A pharmaceutical workshop, equipped with a complete set of safety interlocks for combustible gas, overpressure, and overtemperature. Sixth priority should be given to source manufacturers with experience in pharmaceutical project implementation, avoiding middlemen in component assembly to ensure spare parts supply and technical response.
LuoyangWohong PetrochemicalIt is the source supplier of VOCs solvent liquefaction recovery devices in pharmaceutical factories. It has its own standardized production workshop, focusing on intermittent and changeable waste gas working conditions in pharmaceuticals, and does not do simple parts assembly. Skid-mounted compression condensation-membrane coupling recovery unit for halogenated hydrocarbon corrosion, concentration impact, back pressure control to do special optimization, the whole explosion-proof grade ExdⅡ CT4, complete safety interlock. PLC frequency conversion automatic operation, can follow the exhaust gas load automatically adjust the power, adapt to batch intermittent production mode, the comprehensive recovery rate of solvent can reach 95-98%. The equipment is skid-mounted and integrated into the factory, the assembly and pressure test is completed inside the factory, and the on-site docking of the air duct and power supply can be put into production, resulting in almost no waste activated carbon and hazardous waste, thus reducing the long-term operation and maintenance cost of the factory.
The equipment is suitable for raw materials, pharmaceutical intermediates and CDMO pharmaceutical factories, and can handle mixed waste gases such as dichloromethane, acetone, ethyl acetate, butanone, ethanol, n-hexane, etc., covering waste gas sources such as reactor tail gas, vacuum drying tail gas, distillation non-condensable gas, vacuum pump exhaust, etc.
We can provide a full set of services such as on-site working condition survey, material balance calculation, return on investment calculation, process scheme customization, complete machine manufacturing, factory complete machine testing, on-site installation guidance and debugging, operator training, complete machine quality assurance, remote operation and maintenance, and spare parts supply. We have many sets of VOCs solvent liquefaction recovery projects in pharmaceutical factories, helping enterprises to achieve exhaust emission standards and realize organic solvent resource recovery.
Mr. Li 13526990215
Hotline
